{
  "title": "Behind The Idea #93: Ligand's Shots On Goal Target",
  "description": "Ligand Pharmaceuticals has been both a strong performer over the past decade and a target of short sellers for some time. The stock has struggled over the last 18 months, though, and Seeking Alpha author 8 Diamonds Advisors feels that the stock has become a strong buy again. The thesis rests on the company's shots on goal approach and its more diversified model. We discuss whether this holds up and what that means for investors.\nTopics covered: \n3:15 - Key elements of 8 Diamonds Advisor's thesis and understanding the company's products\n6:15 - \"Shots on goal\" - what does that mean and how does it work?\n15:45 - The challenges in analyzing the business model\n19:45 - Management's place in the thesis\n24:15 - What's gone on the past few years?\n26:45 - The short theses over the year\n35:45 - The Promacta divestment and a share buyback (?!)",
  "pubDate": "Tue, 08 Oct 2019 08:00:00 -0000",
  "itunes:title": "Ligand's Shots On Goal Target",
  "itunes:episodeType": "full",
  "itunes:episode": 93,
  "itunes:author": "Seeking Alpha",
  "itunes:subtitle": "We break down a long idea on the pharmaceutical company and see whether its 'diversified' model is what it's cracked up to be.",
  "itunes:summary": "Ligand Pharmaceuticals has been both a strong performer over the past decade and a target of short sellers for some time. The stock has struggled over the last 18 months, though, and Seeking Alpha author 8 Diamonds Advisors feels that the stock has become a strong buy again. The thesis rests on the company's shots on goal approach and its more diversified model. We discuss whether this holds up and what that means for investors.\nTopics covered: \n3:15 - Key elements of 8 Diamonds Advisor's thesis and understanding the company's products\n6:15 - \"Shots on goal\" - what does that mean and how does it work?\n15:45 - The challenges in analyzing the business model\n19:45 - Management's place in the thesis\n24:15 - What's gone on the past few years?\n26:45 - The short theses over the year\n35:45 - The Promacta divestment and a share buyback (?!)",
  "content:encoded": "<p>Ligand Pharmaceuticals has been both a strong performer over the past decade and a target of short sellers for some time. The stock has struggled over the last 18 months, though, and Seeking Alpha author 8 Diamonds Advisors feels that the stock has become a strong buy again. The thesis rests on the company's shots on goal approach and its more diversified model. We discuss whether this holds up and what that means for investors.</p><p>Topics covered: </p><p>3:15 - Key elements of 8 Diamonds Advisor's thesis and understanding the company's products</p><p>6:15 - \"Shots on goal\" - what does that mean and how does it work?</p><p>15:45 - The challenges in analyzing the business model</p><p>19:45 - Management's place in the thesis</p><p>24:15 - What's gone on the past few years?</p><p>26:45 - The short theses over the year</p><p>35:45 - The Promacta divestment and a share buyback (?!)</p>",
  "itunes:duration": 2838,
  "itunes:explicit": "no",
  "guid": "49cbdbd0-e603-11e9-9b2b-ffecacf3877c",
  "enclosure": ""
}